MedTrace Logo

Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors

NCT01281488 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2017-10-13

No results posted yet for this study

Summary

RATIONALE: Using fluorescence imaging may determine the extent of kidney tumors and help in planning surgery.

PURPOSE: This phase I trial is studying the best way to give indocyanine green (ICG) fluorescence imaging in finding tumors in patients with kidney tumors

Conditions

  • Recurrent Renal Cell Cancer
  • Stage I Renal Cell Cancer
  • Stage II Renal Cell Cancer

Interventions

PROCEDURE

fluorescence imaging

Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system

PROCEDURE

laparoscopic surgery

Undergo standard approach robot-assisted laparoscopic partial nephrectomy

DRUG

indocyanine green

Given IV

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Clayton Lau, MD · City of Hope Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-20
Primary Completion
2017-10-09
Completion
2017-10-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01281488 on ClinicalTrials.gov